Not yet recruitingInterventionalPhase 1Phase 2Last updated Aug 5, 2025

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）

A Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of TYK-00540 Combined With Enzalutamide in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) That Has Failed Previous Novel Endocrine Therapy

Overview

ClinicalTrials.gov ID: NCT07104643
Lead Sponsor: TYK Medicines, IncINDUSTRY
Brief Summary: This study is to evaluate the safety, and preliminary antitumor activity of TYK-00540 combined with Enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Aug 2025Estimated
Primary Completion Date: Nov 2026Estimated
Completion Date: Nov 2026Estimated

Study Record Dates

First Submitted: Jul 29, 2025
First Submitted that Met QC Criteria: Jul 29, 2025
First Posted: Aug 5, 2025Actual
Last Update Submitted that Met QC Criteria: Jul 29, 2025
Last Update Posted: Aug 5, 2025Actual
Last Verified: Jul 2025

NCT07104617Not yet recruiting

Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）

NCT02525068Unknown status

A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC

NCT06702995Recruiting

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT02711956Completed

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02012296Completed

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

NCT03177187Terminated

Combination Study of AZD5069 and Enzalutamide.